Ann: ePAT selected for CSIRO's ON Accelerator Program-MNQ.AX, page-41

I am very interested in this company but one thing is deterring me from investing at this moment and that's the fact that I cannot find any clinical evidence to back up what the App can purport to do.

I have held Rap since it was 3 cents and the key difference I see here is that with Rap you can test the respiratory diagnosis completely accurately from traditional methods after it provides the diagnosis from the App. My point is, in this situation how will they know from a baby or someone with dementia that they are actually suffering pain? in that they can compare the diagnosis from the App towards more concrete evidence showing that they actually are suffering pain and therefore provide clarity in their clinical studies.

I apologise if this has been covered by someone else but nonetheless very interested.